Short fractionation radiotherapy for early prostate cancer in the time of COVID-19: long-term excellent outcomes from a multicenter Italian trial suggest a larger adoption in clinical practice

Autor: Michela Marcenaro, Elena Tornari, Umberto Ricardi, Salvina Barra, Alessia Guarnieri, Stefano Maria Magrini, Liliana Belgioia, Renzo Corvò, Michela Buglione Di Monale E Bastia
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Oncology
Male
medicine.medical_treatment
030218 nuclear medicine & medical imaging
Prostate cancer
0302 clinical medicine
80 and over
Prospective Studies
Dose Fractionation
Tomography
Aged
80 and over
SBRT
Radiation
Hi-tech
General Medicine
Cone-Beam Computed Tomography
Middle Aged
X-Ray Computed
Clinical Practice
Italy
Radiology Nuclear Medicine and imaging
030220 oncology & carcinogenesis
Toxicity
Biochemical recurrence
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19)
Radiobiology and Safety
Radiosurgery
Hypofractionated radiotherapy
03 medical and health sciences
Internal medicine
COVID-19
Aged
Dose Fractionation
Radiation
Humans
Pandemics
Prostatic Neoplasms
SARS-CoV-2
Tomography
X-Ray Computed
medicine
Radiology
Nuclear Medicine and imaging
Genitourinary system
business.industry
Fractionation Radiotherapy
medicine.disease
Radiation therapy
business
Zdroj: La radiologia medica
La Radiologia Medica
ISSN: 1826-6983
0033-8362
DOI: 10.1007/s11547-020-01216-9
Popis: Introduction To evaluate stereotactic body radiotherapy (SBRT) in low-risk Prostate Cancer patients as preferred treatment option in emergency health conditions. Materials and methods From April 2013 to September 2015, 28 patients with low-risk prostate cancer were prospectively enrolled. The SBRT prescribed dose was 36.25 Gy in 5 fractions, twice a week. Primary endpoints were acute and late toxicity. Secondary endpoints were biochemical recurrence free survival (bRFS) and overall survival. Results Median follow-up was 65.5 months (range 52–81). No acute G3 or G4 toxicity was recorded. Acute G1 or G2 genitourinary (GU) toxicity occurred in 43% and acute G1–G2 gastrointestinal (GI) toxicity in 14%. Late G1 and G3 GU toxicity in 18% and 3.5%, respectively. The G3 toxicity was not directly attributable to radiotherapy. Late G1 GI toxicity occurred in 18%. 5yy bRFS was 96.5% (95% CI 82.3–99.4%). Conclusions Stereotactic body radiotherapy for early prostate cancer reported safe toxicity profile and a good clinical outcome at the median follow-up of 5 years. It may be an useful option if radiotherapy is required in emergency medical conditions.
Databáze: OpenAIRE
Externí odkaz: